Cannabis and Heart Disease
Two new studies suggest that even healthy young cannabis users face significantly higher risks for heart attack and stroke. While causality remains unproven, researchers emphasize that “legal doesn’t mean safe.”
Two new studies suggest that even healthy young cannabis users face significantly higher risks for heart attack and stroke. While causality remains unproven, researchers emphasize that “legal doesn’t mean safe.”
Over half of Canadian women who haven’t yet tried virtual care say they’re open to it — a growing trend as more face gaps in traditional health systems. Employers are in a unique position to help close the access gap.
New data from Telus Health’s mental-health index shows that two out of five Canadian employees are living under constant stress — with significantly lower mental health scores and rising risks for anxiety and depression.
A new study finds that what we eat — and how we carry weight — in midlife could have long-lasting effects on memory, brain structure, and cognition later in life.
As more employees take mental health leave, a new survey shows many still work while off — with after-hours pressure and poor sleep compounding workplace burnout.
A major new analysis reveals that the majority of noninvasive treatments for nonspecific low back pain fail to outperform placebo — and only a small number offer modest, evidence-based pain relief.
New studies reveal an association between cannabis use and increased risk of heart attacks, strokes, and arrhythmia. While evidence is still evolving, cardiologists suggest informed discussions with patients are essential.
Mental health disorders now make up nearly 40% of all long-term disability claims in Canada. Adjustment and anxiety disorders are rising — and employers must act now to support workers’ mental health.
From the fizz of soda to the pop of champagne, bubbles offer a multisensory experience that captivates more than just your taste buds.
TELUS Health’s 2025 Drug Data Trends report shows modest increases in employer drug plan spending in 2024. While generic and biosimilar options helped slow growth, specialty drugs—including high-cost weight-loss and inflammatory medications—drove much of the increase.